Thymoma and thymic carcinoma.
作者信息
Jain Satinder Kumar
机构信息
Department of Thoracic Surgery, Manipal Hospitals, Sector - 6, Dwarka, New Delhi, 110018 India.
出版信息
Indian J Thorac Cardiovasc Surg. 2024 Nov;40(6):658-659. doi: 10.1007/s12055-024-01768-9. Epub 2024 Jun 4.
Abstract
摘要
相似文献
1
Thymoma and thymic carcinoma.胸腺瘤和胸腺癌。
Indian J Thorac Cardiovasc Surg. 2024 Nov;40(6):658-659. doi: 10.1007/s12055-024-01768-9. Epub 2024 Jun 4.
2
Clinical features and prognostic factors in thymoma and thymic carcinoma.胸腺瘤和胸腺癌的临床特征及预后因素
Indian J Thorac Cardiovasc Surg. 2024 Nov;40(6):660-668. doi: 10.1007/s12055-024-01741-6. Epub 2024 May 14.
3
Systemic treatments for thymoma and thymic carcinoma: A systematic review.胸腺瘤和胸腺癌的系统治疗：系统评价。
Lung Cancer. 2018 Dec;126:25-31. doi: 10.1016/j.lungcan.2018.10.018. Epub 2018 Oct 18.
4
Surgical, Radiation, and Systemic Treatments of Patients With Thymic Epithelial Tumors: A Systematic Review.胸腺上皮肿瘤患者的手术、放疗及全身治疗：一项系统评价
J Thorac Oncol. 2023 Mar;18(3):299-312. doi: 10.1016/j.jtho.2022.10.016. Epub 2022 Nov 4.
5
EZH2 and POU2F3 Can Aid in the Distinction of Thymic Carcinoma from Thymoma.EZH2和POU2F3有助于鉴别胸腺癌和胸腺瘤。
Cancers (Basel). 2023 Apr 13;15(8):2274. doi: 10.3390/cancers15082274.
6
The Prognostic Value of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma: A Propensity-Matched Study Based on SEER Database.胸腺瘤和胸腺癌术后放疗的预后价值：一项基于监测、流行病学和最终结果（SEER）数据库的倾向评分匹配研究
Cancers (Basel). 2022 Oct 8;14(19):4938. doi: 10.3390/cancers14194938.
7
Comparison of Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy between B3 Thymoma and Thymic Carcinoma.B3 型胸腺瘤与胸腺癌一线含铂化疗疗效和安全性的比较。
Curr Oncol. 2022 Dec 2;29(12):9452-9460. doi: 10.3390/curroncol29120743.
8
Elevated serum CYFRA 21-1 level as a diagnostic marker for thymic carcinoma.血清 CYFRA 21-1 水平升高可作为胸腺癌的诊断标志物。
Thorac Cancer. 2021 Nov;12(21):2933-2942. doi: 10.1111/1759-7714.14158. Epub 2021 Sep 27.
9
Comparison of patterns of relapse in thymic carcinoma and thymoma.胸腺癌与胸腺瘤复发模式的比较。
J Thorac Cardiovasc Surg. 2009 Jul;138(1):26-31. doi: 10.1016/j.jtcvs.2009.03.033.
10
Low incidence of and mortality from a second malignancy after resection of thymic carcinoma†.胸腺癌切除术后第二原发恶性肿瘤的低发病率和死亡率†
Interact Cardiovasc Thorac Surg. 2019 Mar 1;28(3):375-379. doi: 10.1093/icvts/ivy260.
本文引用的文献
1
Clinical TNM staging of thymic epithelial malignancies.胸腺上皮性恶性肿瘤的临床TNM分期
Mediastinum. 2019 Feb 20;3:5. doi: 10.21037/med.2019.01.04. eCollection 2019.
2
Pro-tumor γδ T Cells in Human Cancer: Polarization, Mechanisms of Action, and Implications for Therapy.促肿瘤 γδ T 细胞在人类癌症中的作用：极化、作用机制及治疗意义。
Front Immunol. 2020 Sep 16;11:2186. doi: 10.3389/fimmu.2020.02186. eCollection 2020.
3
Diagnostic Roles of Immunohistochemistry in Thymic Tumors: Differentiation between Thymic Carcinoma and Thymoma.免疫组织化学在胸腺肿瘤中的诊断作用：胸腺癌与胸腺瘤的鉴别
Diagnostics (Basel). 2020 Jul 6;10(7):460. doi: 10.3390/diagnostics10070460.
4
Fibroblasts in the Tumor Microenvironment.肿瘤微环境中的成纤维细胞。
Adv Exp Med Biol. 2020;1234:15-29. doi: 10.1007/978-3-030-37184-5_2.
5
Cytokines in clinical cancer immunotherapy.细胞因子在临床癌症免疫治疗中的作用。
Br J Cancer. 2019 Jan;120(1):6-15. doi: 10.1038/s41416-018-0328-y. Epub 2018 Nov 9.
6
Historical perspectives: The evolution of the thymic epithelial tumors staging system.历史视角：胸腺上皮肿瘤分期系统的演变。
Lung Cancer. 2014 Feb;83(2):126-32. doi: 10.1016/j.lungcan.2013.09.013. Epub 2013 Oct 15.
7
Cancer; a biological approach. I. The processes of control.癌症：一种生物学方法。I. 控制过程。
Br Med J. 1957 Apr 6;1(5022):779-86. doi: 10.1136/bmj.1.5022.779.
Zotero 插件